MET and non-small cell lung carcinoma: This strategy is based on Phase II studies in NSCLC (onartuzumab) and GEC (rilotumumab) suggesting that MET overexpression is predictive of clinical benefit from anti-HGF/MET therapy [47, 62, 63].